The UK and US have signed a landmark trade agreement that will guarantee no tariffs on UK medicine products entering the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to boost funding on medicines through the National Health Service (NHS). This move secures that import taxes on these key products will remain at nothing for a period of 36 months.
This development comes after previous warnings to dramatically increase duties on patented drug products, with increases discussed as high as one hundred percent.
"This deal between the Britain bolsters the global environment for cutting-edge drugs and brings much-needed fairness to American-British medicine commerce," an announcement noted.
Commercial Importance
Medicines are one of the UK's biggest export categories to the US, which is by far the primary destination for major UK drugmakers.
Statistics indicate that in the year leading up to last September, the UK shipped medicines worth £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This guarantee protects employment, increases investment and facilitates the UK to become a global hub for life sciences," a minister stated.
Detailed UK Commitments
The agreement entails several specific pledges from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double overall public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
The deal follows a long-running tension between the drug companies and the UK government over spending levels and approval rates.
These tensions were exacerbated by arguments that American consumers were paying a premium for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been halted or abandoned, while substantial expansions have been pledged toward American operations.
One official acknowledged that the NHS needed to spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its total funding over the last ten years.
